Identification of low-dose multidrug combinations for sunitinib-naive and pre-treated renal cell carcinoma | British Journal of Cancer
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting | Future Oncology
Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers | BMC Cancer | Full Text
Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response ...
Experience with sunitinib in the treatment of metastatic renal cell carcinoma - Manuela Schmidinger, James Larkin, Alain Ravaud, 2012
New Data on KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus Sunitinib in First-Line Treatment for Patients With Advanced Renal Cell Carcinoma From Pivotal Phase 3 CLEAR/KEYNOTE-581 Trial Presented at 2021 ASCO Annual Meeting
Frontiers | Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China
Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers | BMC Cancer | Full Text
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial - The Lancet
Ginsenoside Rh2 sensitizes the anti-cancer effects of sunitinib by inducing cell cycle arrest in renal cell carcinoma | Scientific Reports
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma - ScienceDirect
Kaplan-Meier analysis of overall survival by first targeted therapy | Download Scientific Diagram
Frontiers | Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First- Line Setting
Overall survival rates of advanced gastrointestinal stromal tumor... | Download Scientific Diagram
Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis - Annals of Oncology
Biomedicines | Free Full-Text | Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
322-Renal cell metastatic sUNITinib | eviQ
Overall survival rates of advanced gastrointestinal stromal tumor... | Download Scientific Diagram
a) Progression-free survival (PFS) in 90 mRCC patients treated with... | Download Scientific Diagram
Phase II study of sunitinib as second-line treatment for advanced gastric cancer | SpringerLink
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. | Semantic Scholar
Survival distributions for progression-free (PFS) and overall survival... | Download Scientific Diagram
Diagnostics | Free Full-Text | Clear Cell Renal Cell Carcinoma Spinal Metastases: Which Factors Matter to the Overall Survival? A 10-Year Experience of a High-Volume Tumor Spine Center
Continued Progression-Free and Overall Survival Superiority of First-Line Pembrolizumab/Axitinib vs Sunitinib - The ASCO Post
